TP53 and carcinoma: For example, the classical tumor progression model of sporadic CRC finds that frequent mutations occur in APC, TP53, KRAS gene, and APC mutation contributes to adenoma formation followed by the acquisition of KRAS mutations promoting the transition from intermediate adenomas to carcinomas with TP53 inactivation as a late event [2].